150 related articles for article (PubMed ID: 34925738)
1. Tumor-Specificity Growth Factor Combined with Tumor Markers in Nuclear Medicine Imaging to Identify Prostate Cancer Osteonosus.
Zhang X; Chen Z
J Healthc Eng; 2021; 2021():7380120. PubMed ID: 34925738
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
4. [Application of apparent diffusion coefficient combined with serum tumor markers detection in evaluating neoadjuvant chemotherapy for osteosarcoma].
Wang Z; Liu L; Song YX; Zhang H; She W; Qian YW
Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(13):1012-1016. PubMed ID: 32294859
[No Abstract] [Full Text] [Related]
5. Value of Combined Detection of Serum CEA, CA72-4, CA19-9 and TSGF in the Diagnosis of Gastric Cancer.
Yin LK; Sun XQ; Mou DZ
Asian Pac J Cancer Prev; 2015; 16(9):3867-70. PubMed ID: 25987051
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 18F-FDG PET/CT imaging with different dual time 18F-FDG PET/CT with forced diuresis in clinical diagnosis of prostate cancer.
Yu L; Huang S; Wu S; Yue J; Yin L; Lin Z
Medicine (Baltimore); 2023 Jan; 102(2):e32331. PubMed ID: 36637950
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[
Sonni I; Minamimoto R; Baratto L; Gambhir SS; Loening AM; Vasanawala SS; Iagaru A
Mol Imaging Biol; 2020 Apr; 22(2):397-406. PubMed ID: 31236756
[TBL] [Abstract][Full Text] [Related]
8. Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography-Should Patients Receive Further Evaluation?
Reesink DJ; Fransen van de Putte EE; Vegt E; De Jong J; van Werkhoven E; Mertens LS; Bex A; van der Poel HG; van Rhijn BW; Horenblas S; Meijer RP
J Urol; 2016 Apr; 195(4 Pt 1):907-12. PubMed ID: 26598424
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Value of Multislice Spiral Computed Tomography Combined with Serum AFP, TSGF, and GP73 Assay in the Diagnosis of Primary Liver Cancer.
Yu C; Sun C
Evid Based Complement Alternat Med; 2022; 2022():6581127. PubMed ID: 35711497
[TBL] [Abstract][Full Text] [Related]
10. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
[TBL] [Abstract][Full Text] [Related]
11. The meta-analysis of the effect of 68Ga-PSMA-PET/CT diagnosis of prostatic cancer compared with bone scan.
Zhao R; Li Y; Nie L; Qin K; Zhang H; Shi H
Medicine (Baltimore); 2021 Apr; 100(15):e25417. PubMed ID: 33847640
[TBL] [Abstract][Full Text] [Related]
12. Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis.
Turkbey B; Mena E; Shih J; Pinto PA; Merino MJ; Lindenberg ML; Bernardo M; McKinney YL; Adler S; Owenius R; Choyke PL; Kurdziel KA
Radiology; 2014 Mar; 270(3):849-56. PubMed ID: 24475804
[TBL] [Abstract][Full Text] [Related]
13. Serum TSGF and miR-214 levels in patients with hepatocellular carcinoma and their predictive value for the curative effect of transcatheter arterial chemoembolization.
Tang L; Zhang XM
Ann Palliat Med; 2020 Jul; 9(4):2111-2117. PubMed ID: 32762227
[TBL] [Abstract][Full Text] [Related]
14. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of integrated PET/MRI for detection and localization of prostate cancer: Comparative study of multiparametric MRI and PET/CT.
Lee MS; Cho JY; Kim SY; Cheon GJ; Moon MH; Oh S; Lee J; Lee S; Woo S; Kim SH
J Magn Reson Imaging; 2017 Feb; 45(2):597-609. PubMed ID: 27586519
[TBL] [Abstract][Full Text] [Related]
16. Does focal incidental 18F-FDG PET/CT uptake in the prostate have significance?
Brown AM; Lindenberg ML; Sankineni S; Shih JH; Johnson LM; Pruthy S; Kurdziel KA; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
Abdom Imaging; 2015 Oct; 40(8):3222-9. PubMed ID: 26239399
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET-CT in Unknown-Source of Elevated Serum Carcinoembryonic Antigen (CEA) Level.
Fu L; Li W; Tian X
J Coll Physicians Surg Pak; 2018 Dec; 28(12):910-913. PubMed ID: 30501825
[TBL] [Abstract][Full Text] [Related]
18. Comparison of whole-body 18F-FDG PET/CT and PET/MRI for distant metastases in patients with malignant tumors: a meta-analysis.
Zhang C; Liang Z; Liu W; Zeng X; Mo Y
BMC Cancer; 2023 Jan; 23(1):37. PubMed ID: 36624425
[TBL] [Abstract][Full Text] [Related]
19. Nuclear medicine studies of the prostate, testes, and bladder.
Jana S; Blaufox MD
Semin Nucl Med; 2006 Jan; 36(1):51-72. PubMed ID: 16356796
[TBL] [Abstract][Full Text] [Related]
20. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?
Aryal A; Kumar VS; Shamim SA; Gamanagatti S; Khan SA
Clin Orthop Relat Res; 2021 Aug; 479(8):1768-1779. PubMed ID: 33635285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
